MFY Stock Overview
Manufactures and sells pharmaceuticals and healthcare products in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Mochida Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥20.20 |
| 52 Week High | JP¥22.40 |
| 52 Week Low | JP¥16.60 |
| Beta | -0.0068 |
| 1 Month Change | -3.81% |
| 3 Month Change | -1.94% |
| 1 Year Change | 0% |
| 3 Year Change | -24.06% |
| 5 Year Change | -40.94% |
| Change since IPO | 11.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| MFY | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 4.0% | 3.0% |
| 1Y | 0% | -12.8% | 13.2% |
Return vs Industry: MFY exceeded the German Pharmaceuticals industry which returned -14% over the past year.
Return vs Market: MFY underperformed the German Market which returned 13.1% over the past year.
Price Volatility
| MFY volatility | |
|---|---|
| MFY Average Weekly Movement | 3.8% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: MFY has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: MFY's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1913 | 1,522 | Naoyuki Mochida | www.mochida.co.jp |
Mochida Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals and healthcare products in Japan. The company offers pharmaceuticals products for the treatment of cardiovascular, obstetrics, gynecology, dermatology, psychiatry, and gastroenterology. It offers Lialda for the treatment of ulcerative colitis; Goofice and Movicol for the treatment of chronic constipation; Lexapro, an antidepressant drug; Epadel drug for hyperlipidemia and arteriosclerosis obliterans; Urece for the treatment of gout and hyperuricemia; and Treprost for the treatment of pulmonary arterial hypertension.
Mochida Pharmaceutical Co., Ltd. Fundamentals Summary
| MFY fundamental statistics | |
|---|---|
| Market cap | €725.42m |
| Earnings (TTM) | €27.99m |
| Revenue (TTM) | €645.08m |
25.9x
P/E Ratio1.1x
P/S RatioIs MFY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MFY income statement (TTM) | |
|---|---|
| Revenue | JP¥104.51b |
| Cost of Revenue | JP¥52.67b |
| Gross Profit | JP¥51.84b |
| Other Expenses | JP¥47.31b |
| Earnings | JP¥4.53b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 07, 2025
| Earnings per share (EPS) | 127.89 |
| Gross Margin | 49.61% |
| Net Profit Margin | 4.34% |
| Debt/Equity Ratio | 0% |
How did MFY perform over the long term?
See historical performance and comparisonDividends
2.4%
Current Dividend Yield63%
Payout RatioDoes MFY pay a reliable dividends?
See MFY dividend history and benchmarks| Mochida Pharmaceutical dividend dates | |
|---|---|
| Ex Dividend Date | Mar 28 2025 |
| Dividend Pay Date | Jun 30 2025 |
| Days until Ex dividend | 64 days |
| Days until Dividend pay date | 158 days |
Does MFY pay a reliable dividends?
See MFY dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/21 12:52 |
| End of Day Share Price | 2025/01/21 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Mochida Pharmaceutical Co., Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Toshiyuki Hibino | Mitsubishi UFJ Morgan Stanley Securities Company Limited |
| Taku Ouchi | SMBC NIKKO |
| Jayaprabha Dhavale | Virtua Research Inc. |